Shotlee LogoShotlee
Blog
Download on theApp Store
Get it onGoogle Play
Skip to main content
Ozempic Era Over? BMJ Study on GLP-1 Weight Regain - Featured image
GLP-1 Medications

Ozempic Era Over? BMJ Study on GLP-1 Weight Regain

Dr. Adrian Vale, MD
Reviewed by Dr. Adrian Vale, MDInternal Medicine · Board-Certified Obesity Medicine
·January 19, 2026·3 min read

On this page

  • Weight Regain: The Temporary Effect of GLP-1 Drugs
  • Treating Symptoms, Not Obesity's Root Causes
  • From Individual to Systemic Solutions
  • How Convenience Fuels the Obesity Epidemic
  • Ultra-Processed Foods and Addictive Design

Track Smart

Calculate active GLP-1 levels automatically with Shotlee.

Download →

The Ozempic hype may fade as a BMJ study shows users regain lost weight within 1.5 years after stopping GLP-1 drugs. These medications reduce appetite but require lifelong use and lifestyle changes for lasting results. Obesity stems from systemic issues like convenience culture and ultra-processed foods, not just willpower.

Share

On this page

  • Weight Regain: The Temporary Effect of GLP-1 Drugs
  • Treating Symptoms, Not Obesity's Root Causes
  • From Individual to Systemic Solutions
  • How Convenience Fuels the Obesity Epidemic
  • Ultra-Processed Foods and Addictive Design

In the three years since Ozempic captured public attention, the brand has become shorthand for all GLP-1 receptor agonists like Wegovy and Mounjaro. Once hailed as a wonder drug transforming waistlines and markets—from falling Krispy Kreme stocks to airline fuel savings—these treatments mimic a hormone that curbs appetite and controls blood sugar. Users often describe silencing "food noise," eliminating the willpower struggle in dieting.

Weight Regain: The Temporary Effect of GLP-1 Drugs

Recent data from the British Medical Journal published January 7 indicates users lose about 20% of body weight on these drugs. However, stopping treatment leads to full regain within 1.5 years. Ozempic delivers nation-altering benefits only with lifelong use.

  • Lifelong commitment raises costs—estimated at £10bn yearly for all eligible UK patients, half the drugs budget.
  • NICE guidelines limit some GLP-1s for weight loss to two years maximum.
  • Sustainable results demand lifestyle changes like "eat less, move more," mirroring past failed initiatives.

In essence, GLP-1 drugs resemble traditional diets: effective for loss but challenging for maintenance, as any yo-yo dieter knows.

Treating Symptoms, Not Obesity's Root Causes

Obesity demands addressing underlying drivers, not just symptoms. Factors include poverty, advertising, fast food, smartphone addiction, and sedentary lifestyles—not individual willpower alone.

UK stats highlight the crisis: 27% of men and 29% of women are obese today, up from 6% and 9% in 1980. Humanity thrived for 300,000 years with minimal obesity until industrialization eroded daily movement.

Precision tracking for your journey

Join thousands using Shotlee to accurately track GLP-1 medications and side effects.

📱 Get the Shotlee App

Track your GLP-1 medications, peptides, and health metrics on the go with our mobile app!

Download on theApp Store
Get it onGoogle Play

How Convenience Fuels the Obesity Epidemic

  • Mechanized jobs and conveniences like cars, escalators, and vacuums reduced incidental activity.
  • Instant access via screens to food, banking, and shopping—from the sofa—increases eating while sedentary.
  • Shorter work hours yield more leisure, yet we feel too time-poor for exercise or home cooking.

The pandemic blurred work-play boundaries, amplifying always-on culture.

Ultra-Processed Foods and Addictive Design

Food has shifted to manufactured ultra-processed items, now over half of UK caloric intake. These hit the "bliss point"—optimal fat-salt-sugar ratios for maximum brain pleasure, overriding satiety signals.

Psychophysicist Howard Moskowitz defined this engineering. Historian David Courtwright terms it "limbic capitalism," where Big Food profits from addiction reward pathways, akin to social media or gambling. Early trials suggest GLP-1s may curb such addictions, but relying on Big Pharma for Big Food and Tech fixes feels dystopian.

From Individual to Systemic Solutions

689 UK anti-obesity initiatives since 1992 failed because obesity is collective, needing societal responses. Yet personal rebellion counts: cooking dinner or walking to takeaways defies profiteering from poor health.

For those on lifelong GLP-1s, apps like Shotlee help track doses consistently. Still, true change integrates drugs with environmental shifts for enduring weight management.

Source Information

Originally published by New Statesman.Read the original article →

Read next

Keep exploring

More on Ozempic

Articles covering Ozempic dosing, side effects, and clinical updates.

Alli Weight Loss Pill: FDA Flags Serious Kidney Risks
Health & Wellness

Alli Weight Loss Pill: FDA Flags Serious Kidney Risks

The Food and Drug Administration (FDA) has issued a new warning regarding potential serious kidney complications associated with Alli, the sole over-the-counter weight loss medication available in the United States. The drug's label has been updated to reflect these risks, urging caution for consumers.

8 min read
Beyond Weight Loss: How GLP-1s Impact Your Blood Pressure
Health & Wellness

Beyond Weight Loss: How GLP-1s Impact Your Blood Pressure

GLP-1 receptor agonists, known for their role in diabetes and weight management, are increasingly recognized for their broader health benefits, including effects on blood pressure. This article delves into how these medications work, their impact on cardiovascular health, and whether they are safe for individuals with hypertension.

8 min read
Wegovy Pill Arrives in the UK: A New Era for Weight Management?
Health & Wellness

Wegovy Pill Arrives in the UK: A New Era for Weight Management?

The UK has officially approved a pill version of the popular Wegovy weight-loss drug, marking a significant advancement in accessible obesity treatment. This development offers a convenient alternative to weekly injections for many.

6 min read

Same topic: Ozempic

All Ozempic articles →
How to Keep Weight Off After Ozempic: Proven Strategies
GLP-1 Medications

How to Keep Weight Off After Ozempic: Proven Strategies

Stopping Ozempic often leads to weight regain—up to 7% in trials or two-thirds within a year. While continuing semaglutide helps sustain losses, lifestyle changes and maintenance dosing offer alternatives. Work with your healthcare team for a personalized plan to keep the weight off long-term.

6 min read
Ozempic Fuels Tapatío Hot Sauce Boom: L.A. Icon's Story
GLP-1 Medications

Ozempic Fuels Tapatío Hot Sauce Boom: L.A. Icon's Story

Ozempic isn't just transforming waistlines—it's igniting a surge in hot sauce sales like Tapatío's. As millions embrace GLP-1 drugs, cravings for bold flavors skyrocket, propelling L.A.'s iconic brand into national expansion under new owners Highlander Partners. This is the untold story of family legacy meeting metabolic health trends.

5 min read
Taking GLP-1s? Doctors Stress Movement and Mental Health Too
GLP-1 Medications

Taking GLP-1s? Doctors Stress Movement and Mental Health Too

Jelon Smart from Savannah dropped 110 pounds on Ozempic—but credits her intensive workout regimen too. Facing severe ankle swelling from Achilles tendinitis at 285 pounds, she transformed her life. Doctors remind GLP-1 users: movement and mental health are essential alongside medication.

5 min read

More in GLP-1 Medications

Ozempic and the Shift: Real Data on America's Obesity Rates
Health & Wellness

Ozempic and the Shift: Real Data on America's Obesity Rates

New data from EPIC Research highlights a correlation between rising GLP-1 prescriptions and a modest decline in US obesity rates, offering hope amidst ongoing challenges.

7 min read
Wegovy, Zepbound & More: Hers Makes GLP-1s Accessible from $39
Health & Wellness

Wegovy, Zepbound & More: Hers Makes GLP-1s Accessible from $39

The journey to weight loss can be challenging, and for many, advanced medications like GLP-1 injectables offer a crucial pathway. However, their high cost often presents a significant barrier. Hers is changing this landscape by making popular GLP-1 and other weight loss treatments more accessible and affordable than ever before.

7 min read
Beyond GLP-1s: Unlocking Better Diabetes Control with Korlym
Medical Insights

Beyond GLP-1s: Unlocking Better Diabetes Control with Korlym

For individuals struggling with difficult-to-control type 2 diabetes and weight management, even powerful GLP-1 medications might not be enough. New research highlights the significant role of hypercortisolism and the promising potential of Korlym in optimizing treatment outcomes.

6 min read
Share this article
  1. Home
  2. Blog
  3. Ozempic Era Over? BMJ Study on GLP-1 Weight Regain
Dr. Adrian Vale, MD — Internal Medicine · Board-Certified Obesity Medicine
Medically reviewed

Dr. Adrian Vale, MD

Internal Medicine · Board-Certified Obesity Medicine

Dr. Adrian Vale is a board-certified internal medicine physician with a clinical focus on obesity medicine and metabolic health. He reviews Shotlee guides and articles on GLP-1 medications, peptide therapy, and weight-management protocols for clinical accuracy.

View all articles reviewed by Dr. Adrian Vale, MD
Shotlee LogoShotlee

Your comprehensive health tracking companion. Track, analyze, and optimize your journey with advanced metrics and community support.

Product

  • Medication Trackers
  • Health Guides
  • Calculators
  • Compare Medications
  • Pricing

Resources

  • Health Blog
  • Support Center

Legal

  • Privacy Policy
  • Terms of Service
  • Community Guidelines
  • Refund Policy

© 2026 Shotlee. All rights reserved.

Made with for the community♥ for the community